Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZALEA: abelacimab versus rivaroxaban in atrial fibrillation
2023-509066-38-00Phase 2Authorised
- Sponsor
- Anthos Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of abelacimab and rivaroxaban in Atrial fibrillation (AFib) (3 arms), sponsored by Anthos Therapeutics. Primary endpoint: Time to first event of composite of ISTH-defined major bleeding or clinically relevant non-major bleeding. Planned start Apr 2021; status: authorised.
02
Drugs
abelacimabrivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2023-509066-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509066-38-00.